Woodline Partners LLC is a private equity firm that focuses on investments in lower middle market companies across a range of industries. The firm seeks to partner with management teams to build long-term value for their investors.

Woodline Partners is an investment firm that implements a fundamental sub-sector equity strategy. We represent a tenured team with specialized experience covering North American, European, and Asian markets. Our Portfolio Managers have a shared set of values, a rigorous, bottom-up process, and an established network of corporate executive and industry relationships. Woodline aims to hedge out unpredictable factors and find clarity in company-specific details to assess the
long-term competitiveness of companies under coverage.

Sharecare

Point Biopharma

Amylyx Pharmaceuticals

ATAI Life Sciences

Fusion Pharmaceuticals

Jasper Therapeutics

Kronos Bio

Lyra Therapeutics

Structure Therapeutics

Talkspace

Tango Therapeutics

Eledon Pharmaceuticals

NeoGenomics

HydraFacial

Ventyx Biosciences

Woodline Partners LP 

 Co-Chief Investment Officer Mike Rockefeller joined Barry Ritholtz on Bloomberg Masters in Business to discuss Woodline’s partnership mentality and sub-sector specialist structure.  Listen at:  https://lnkd.in/eVGd-n6d

Congratulations to our Portfolio Manager Hecate Chen, who was recognized as one of @HedgeFundJournal’s 50 Leading Women in Hedge Funds. Hecate’s success speaks to our specialist culture, combining diversified ideas, sectors and decisionmakers to uncover attractive investment opportunities while mitigating risk.

Woodline Partners LLC

COM:WOODLINEPARTNERS

Woodline Partners LLC

Analysis Not Available